@article{3186987,
    title = "The Role of Metoprolol and Enalapril in the Prevention of
Doxorubicin-induced Cardiotoxicity in Lymphoma Patients",
    author = "Georgakopoulos, Peter and Kyriakidis, Michael and Perpinia, Anastasia and and Karavidas, Apostolos and Zimeras, Stelios and Mamalis, Nikolaos and and Kouvela, Marousa and Charpidou, Andriani",
    journal = "ANTICANCER RESEARCH",
    year = "2019",
    volume = "39",
    number = "10",
    pages = "5703-5707",
    publisher = "INT INST ANTICANCER RESEARCH",
    issn = "0250-1291",
    doi = "10.21873/anticanres.13769",
    keywords = "Doxorubicin; cardiotoxicity; lymphoma",
    abstract = "Background/Aim: Anthracyclines, such as doxorubicin, though widely used
in anticancer therapy, they are associated with cardiotoxic
side-effects. The aim of this trial was to investigate long-term
follow-up cardiotoxicity findings in patients treated with doxorubicin
and concomitant metoprolol or enalapril 10 years earlier. Patients and
Methods: Overall, 147 patients were randomized into the treatment arms.
A total of 125 patients treated with doxorubicin without evidence of
heart disease at the start of chemotherapy were analyzed. They were
followed-up for up to 10 years after treatment start. Results and
Conclusion: A total of 47 patients completed the follow-up and 21
patients died, none due to cardiotoxicity events. Clinical signs of
heart failure were not seen in any patients and no statistically
significant differences between baseline and 10-year findings were seen
for echocardiographic variables. No evidence of long-term cardiotoxicity
was seen and nor metoprolol or enalapril offered an additional benefit."
}